FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

Item

http://www.wikidata.org/entity/Q38675400

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

@en

type

Item

label

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

@en

prefLabel

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

@en

P1476

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

@en

P2093

Maria Larrosa-Garcia

http://www.w3.org/2001/XMLSchema#string

Maria R Baer

http://www.w3.org/2001/XMLSchema#string

P2860

SYK is a critical regulator of FLT3 in acute myeloid leukemia

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Acute Myeloid Leukemia

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells

Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

P304

991-1001

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-16-0876

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28576946

http://www.w3.org/2001/XMLSchema#string

P932

5600895

http://www.w3.org/2001/XMLSchema#string